Charles Milstein - Vertex Pharmaceuticals President

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 35px;;'>VRT</div>
VRTX -- USA Stock  

Earning Report: February 4, 2020  

Mr. Michael J. Parini, J.D. is Executive Vice President, Chief Legal and Administrative Officer of the Vertex Pharmaceuticals Incorporated. Mr. Parini is our Executive Vice President and Chief Legal and Administrative Officer, a position he has held since January 2017. From January 2016 to January 2017, he was our Executive Vice President and Chief Legal Officer. From 2004 until he joined Vertex, Mr. Parini served in various roles of increasing responsibility at Pfizer Inc., a pharmaceutical company, most recently as Senior Vice President and Associate General Counsel. Prior to Pfizer, Mr. Parini was an attorney at Akin, Gump, Strauss, Hauer Feld, L.L.P
Age: 42  President Since 2017      
617 341-6100
Parini holds a B.A. from Georgetown University and a J.D. from the Georgetown University Law Center.

Management Efficiency

The company currently holds 649.8 M in liabilities with Debt to Equity (D/E) ratio of 12.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.37 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Ronald JanishPerrigo Company Plc
Jeffrey NeedhamPerrigo Company Plc
Cartikeya ReddyDr Reddys Laboratories Ltd
Saumen ChakrabortyDr Reddys Laboratories Ltd
Michael StewartPerrigo Company Plc
J RamachandranDr Reddys Laboratories Ltd
Joseph LaRosaRegeneron Pharmaceuticals
Louis YuPerrigo Company Plc
Marc CouckePerrigo Company Plc
Amit BiswasDr Reddys Laboratories Ltd
Catherine KnuppZoetis
Heidi ChenZoetis
Michael AbermanRegeneron Pharmaceuticals
K RaoDr Reddys Laboratories Ltd
Andrew FentonZoetis
Jatin ShahPerrigo Company Plc
James MichaudPerrigo Company Plc
Sandra BeatyZoetis
Roman TrawickiZoetis
George YancopoulosRegeneron Pharmaceuticals
Umang VohraDr Reddys Laboratories Ltd

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Did you try this?

Run Balance Of Power Now


Balance Of Power

Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
All  Next Launch Module

Also Currentnly Active

Purchased over 30 shares of
few hours ago
Traded for 80.1
Purchased over 300 shares of
few hours ago
Traded for 9.16
Purchased over 50 shares of
few hours ago
Traded for 58.39
Also please take a look at World Market Map. Please also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of macroaxis ideas.